A Phase 1B, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin.
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2014
At a glance
- Drugs Doxorubicin; Ridaforolimus
- Indications Breast cancer; Endometrial cancer; Ovarian cancer; Sarcoma
- Focus Adverse reactions
- Sponsors Merck & Co
- 09 Jun 2009 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
- 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jan 2008 The expected completion date for this trial is now 1 Dec 2008 as reported by ClinicalTrials.gov.